EWF
AZN icon

Epstein & White Financial’s AstraZeneca AZN Stock Holding History

Epstein & White Financial’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,585
Closed -$397K – 91
2018
Q2 		$397K Sell
5,585
-1,252
-18% -$90.1K 0.29% 56
2018
Q1 		$501K Sell
6,837
-717
-9% -$49.7K 0.32% 54
2017
Q4 		$552K Buy
+7,554
New +$509K 0.32% 50

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Epstein & White Financial's AZN Position: Q3 2018 in Review

Epstein & White Financial sold out of AstraZeneca (AZN) in Q3 2018, closing a stake of 5,585 shares — an estimated $397K sold.

Epstein & White Financial first reported a position in AZN in Q4 2017 and held it in 3 quarters. The position peaked at $552K in Q4 2017. 544 funds tracked by Wall St. Rank hold AZN as of Q3 2018.

  • Epstein & White Financial reported no remaining AstraZeneca position as of Q3 2018 after selling out during the quarter.
  • Epstein & White Financial sold 5,585 AstraZeneca shares in Q3 2018, an estimated $397K.
  • Epstein & White Financial first reported a position in AstraZeneca in Q4 2017 and held it in 3 quarters.
  • Epstein & White Financial's AstraZeneca position peaked at $552K in Q4 2017.
  • 544 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2018.

Based on Epstein & White Financial's 13F filing for Q3 2018, filed 13 Nov 2018.